Coherus Biosciences | CHRS - Cash And Equivalent


Coherus Biosciences reported $88.88M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Fujifilm JPY 160.88B 906M Sep/2025
Gilead Sciences USD 7.56B 234M Dec/2025
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Myriad Genetics USD 124.4M 25.2M Mar/2026
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026
Zoetis USD 1.94B 369M Mar/2026